Literature DB >> 9679951

Absence or reduction of Fhit expression in most clear cell renal carcinomas.

P Hadaczek1, Z Siprashvili, M Markiewski, W Domagala, T Druck, P A McCue, Y Pekarsky, M Ohta, K Huebner, J Lubinski.   

Abstract

The FHIT gene at human chromosome region 3p14.2 straddles the common fragile site, FRA3B, and numerous homozygous deletions in cancer cell lines and primary tumors. Also, the 3p14.2 chromosome breakpoint of the familial clear cell kidney carcinoma-associated translocation, t(3;8)(p14.2;q24), disrupts one FHIT allele between exons 3 and 4, fulfilling one criterion for a familial tumor suppressor gene: that one allele is constitutionally inactivated. Because the FHIT gene sustains biallelic intragenic deletions rather than mutations, there has not been evidence that the FHIT gene frequently plays a role in kidney cancer, although replacement of Fhit expression in a Fhit-negative renal carcinoma cell line suppressed tumor growth in nude mice. We have now assessed 41 clear cell renal carcinomas for expression of Fhit by immunohistochemistry. Normal renal tubule epithelial cells express Fhit uniformly and strongly, whereas 51% of the tumors are completely negative, 34% of tumors show a mixture of positive and negative cells, and 14% are uniformly positive, although usually less strongly positive than the normal epithelial cells. Most interestingly, there was a correlation between complete absence of Fhit and the G1 morphological grade and early clinical stage. Morphological grades G2 and G3 exhibited a mixture of positive and negative cells with a tendency for a higher fraction of negative cells in G3. Fhit inactivation is likely to be an early event in G1 tumors and may be associated with progression in G2 and G3 tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9679951

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Lack of association of fragile histidine triad (FHIT) polymorphisms with lung cancer in the Korean population.

Authors:  Hae-Yun Jung; Jae Sook Sung; Young Mi Whang; Hyoung Doo Shin; Byung Lae Park; Jun Suk Kim; Sang Won Shin; Hee Yun Seo; Hwa Jung Sung; In Keun Choi; Sang Cheul Oh; Jae Hong Seo; Yeul Hong Kim
Journal:  J Hum Genet       Date:  2007-07-04       Impact factor: 3.172

2.  The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.

Authors:  K Dreijerink; E Braga; I Kuzmin; L Geil; F M Duh; D Angeloni; B Zbar; M I Lerman; E J Stanbridge; J D Minna; A Protopopov; J Li; V Kashuba; G Klein; E R Zabarovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

3.  Loss of FHIT expression in transitional cell carcinoma of the urinary bladder.

Authors:  R Baffa; L G Gomella; A Vecchione; P Bassi; K Mimori; J Sedor; C M Calviello; M Gardiman; C Minimo; S E Strup; P A McCue; A J Kovatich; F Pagano; K Huebner; C M Croce
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

4.  The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control.

Authors:  L Sard; P Accornero; S Tornielli; D Delia; G Bunone; M Campiglio; M P Colombo; M Gramegna; C M Croce; M A Pierotti; G Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

5.  Cancer-specific chromosome alterations in the constitutive fragile region FRA3B.

Authors:  K Mimori; T Druck; H Inoue; H Alder; L Berk; M Mori; K Huebner; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

6.  Muir-Torre-like syndrome in Fhit-deficient mice.

Authors:  L Y Fong; V Fidanza; N Zanesi; L F Lock; L D Siracusa; R Mancini; Z Siprashvili; M Ottey; S E Martin; T Druck; P A McCue; C M Croce; K Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

7.  Distribution of Fhit protein in rat tissues and its intracellular localization.

Authors:  F Golebiowski; R Kowara; T Pawelczyk
Journal:  Mol Cell Biochem       Date:  2001-10       Impact factor: 3.396

8.  Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients.

Authors:  Po Zhao; Wu Liu; Ya-Li Lu
Journal:  World J Gastroenterol       Date:  2005-09-28       Impact factor: 5.742

9.  Abnormal Fhit expression is an independent poor prognostic factor for cervical cancer.

Authors:  S Takizawa; S Nakagawa; K Nakagawa; T Yasugi; T Fujii; K Kugu; T Yano; H Yoshikawa; Y Taketani
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

10.  Loss of fragile histidine triad protein in human hepatocellular carcinoma.

Authors:  Po Zhao; Xin Song; Yuan-Yuan Nin; Ya-Li Lu; Xiang-Hong Li
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.